TY - JOUR

T1 - Буспирон в терапии аддиктивных расстройств: прошлое, настоящее, будущее

AU - Petrova, N.N.

N1 - Export Date: 11 March 2024 Адрес для корреспонденции: Petrova, N.N.; Department of Psychiatry and Narcology, 7–9, Universitetskaya emb., Russian Federation; эл. почта: petrova_nn@mail.ru Пристатейные ссылки: Rehm, J., Shield, K.D., Global Burden of Alcohol Use Disorders and Alcohol Liver Disease (2019) Biomedicines, 7 (4), p. 99; Kessler, R.C., Crum, R.M., Warner, L.A., Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey (1997) Arch Gen Psychiatry, 54 (4), pp. 313-321; Hasin, D.S., Stinson, F.S., Ogburn, E., Grant, B.F., Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions (2007) Arch Gen Psychiatry, 64 (7), pp. 830-842; Boschloo, L., Vogelzangs, N., van den Brink, W., Depressive and anxiety disorders predicting first incidence of alcohol use disorders: results of the Netherlands Study of Depression and Anxiety (NESDA) (2013) J Clin Psychiatry, 74 (12), pp. 1233-1240; Alonso, J., Angermeyer, M.C., Bernert, S., 12-Month comorbidity patterns and associated factors in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project (2004) Acta Psychiatr Scand Suppl, 420, pp. 28-37; Kessler, R.C., Nelson, C.B., McGonagle, K.A., The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization (1996) Am J Orthopsychiatry, 66 (1), pp. 17-31; Driessen, M., Meier, S., Hill, A., The course of anxiety, depression and drinking behaviours after completed detoxification in alcoholics with and without comorbid anxiety and depressive disorders (2001) Alcohol Alcohol, 36 (3), pp. 249-255; Kushner, M.G., Abrams, K., Thuras, P., Follow-up study of anxiety disorder and alcohol dependence in comorbid alcoholism treatment patients (2005) Alcohol Clin Exp Res, 29 (8), pp. 1432-1443; Stewart, S.H., Conrod, P.J., Anxiety disorder and substance use disorder co-morbidity: common themes and future directions (2008) Anxiety and Substance Use Disorders: the Vicious Cycle of Comorbidity. Series in Anxiety and Related Disorders, pp. 239-257. , New York: Springer; Smith, J.P., Randall, C.L., Anxiety and alcohol use disorders: comorbidity and treatment considerations (2012) Alcohol Res, 34 (4), pp. 414-431. , PMID: 23584108; Liappas, J., Paparrigopoulos, T., Tzavellas, E., Rabavilas, A., Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification (2005) Prog Neuropsychopharmacol Biol Psychiatry, 29 (1), pp. 55-60; Hoertel, N., Le Strat, Y., Blanco, C., Generalizability of clinical trial results for generalized anxiety disorder to community samples (2012) Depress Anxiety, 29 (7), pp. 614-620; Ipser, J.C., Wilson, D., Akindipe, T.O., Pharmacotherapy for anxiety and comorbid alcohol use disorders (2015) Cochrane Database Syst Rev, 1 (1), p. CD007505; Marcinkiewcz, C.A., Dorrier, C.E., Lopez, A.J., Kash, T.L., Ethanol induced adaptations in 5-HT2c receptor signaling in the bed nucleus of the stria terminalis: implications for anxiety during ethanol withdrawal (2015) Neuropharmacology, 89, pp. 157-167; Bruno, F., Buspirone in the treatment of alcoholic patients (1989) Psychopathology, 22, pp. 49-59. , Suppl 1; Hedlund, L., Wahlström, G., Buspirone as an inhibitor of voluntary ethanol intake in male rats (1996) Alcohol Alcohol, 31 (2), pp. 149-156; Kranzler, H.R., Meyer, R.E., An open trial of buspirone in alcoholics (1989) J Clin Psychopharmacol, 9 (5), pp. 379-380. , PMID: 2677064; Overstreet, D.H., Knapp, D.J., Moy, S.S., Breese, G.R., A 5-HT1A agonist and a 5-HT2c antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats (2003) Psychopharmacology (Berl), 167 (4), pp. 344-352; Malec, T.S., Malec, E.A., Dongier, M., Efficacy of buspirone in alcohol dependence: a review (1996) Alcohol Clin Exp Res, 20 (5), pp. 853-858; Lowery-Gionta, E.G., Marcinkiewcz, C.A., Kash, T.L., Functional alterations in the dorsal raphe nucleus following acute and chronic ethanol exposure (2015) Neuropsychopharmacology, 40 (3), pp. 590-600; Belmer, A., Patkar, O.L., Lanoue, V., Bartlett, S.E., 5-HT1A receptor-dependent modulation of emotional and neurogenic deficits elicited by prolonged consumption of alcohol (2018) Sci Rep, 8 (1), p. 2099; Rodgers, R.J., Cutler, M.G., Jackson, J.E., Behavioural effects in mice of subchronic buspirone, ondansetron and tianeptine. II. The elevated plusmaze (1997) Pharmacol Biochem Behav, 56 (2), pp. 295-303; Gimeno, C., Dorado, M.L., Roncero, C., Treatment of Comorbid Alcohol Dependence and Anxiety Disorder: Review of the Scientific Evidence and Recommendations for Treatment (2017) Front Psychiatry, 8, p. 173; Kranzler, H.R., Burleson, J.A., Del Boca, F.K., Buspirone treatment of anxious alcoholics. A placebo-controlled trial (1994) Arch Gen Psychiatry, 51 (9), pp. 720-731; The Recovery Village. Alcohol Rehab, , https://www.therecoveryvillage.com/alcohol-abuse/treatment-rehab/, M. Carmona, ed. (Electronic resource) (access date: 12.06.2023); Ko, Y.E., Hwa, L.S., Serotonin regulation of intermittent and continuous alcohol drinking in male and female C57BL/6J mice with systemic SB242084 and buspirone (2023) Alcohol Alcohol, 58 (3), pp. 280-288; Heidbreder, C.A., Newman, A.H., Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders (2010) Ann N Y Acad Sci, 1187, pp. 4-34; Yan, Y., Pushparaj, A., Le Strat, Y., Blockade of dopamine d4 receptors attenuates reinstatement of extinguished nicotine-seeking behavior in rats (2012) Neuropsychopharmacology, 37 (3), pp. 685-696; Sokoloff, P., Giros, B., Martres, M.P., Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics (1990) Nature, 347 (6289), pp. 146-151; Volkow, N.D., Fowler, J.S., Wang, G.J., Imaging dopamine's role in drug abuse and addiction (2009) Neuropharmacology, 56, pp. 3-8. , Suppl 1(Suppl 1); Mash, D.C., Are neuroadaptations in D3 dopamine receptors linked to the development of cocaine dependence? (1997) Mol Psychiatry, 2 (1), pp. 7-8. , PMID: 9154209; Mash, D.C., D3 receptor binding in human brain during cocaine overdose (1997) Mol Psychiatry, 2 (1), pp. 5-6. , PMID: 9154208; Boileau, I., Payer, D., Houle, S., Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study (2012) J Neurosci, 32 (4), pp. 1353-1359; Heidbreder, C.A., Gardner, E.L., Xi, Z.X., The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence (2005) Brain Res Brain Res Rev, 49 (1), pp. 77-105; Le Foll, B., Goldberg, S.R., Sokoloff, P., The dopamine D3 receptor and drug dependence: effects on reward or beyond? (2005) Neuropharmacology, 49 (4), pp. 525-541; Bergman, J., Roof, R.A., Furman, C.A., Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors (2013) Int J Neuropsychopharmacol, 16 (2), pp. 445-458; Apter, J.T., Allen, L.A., Buspirone: future directions (1999) J Clin Psychopharmacol, 19 (1), pp. 86-93; Rabiner, E.A., Gunn, R.N., Wilkins, M.R., Drug action at the 5-HT(1A) receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-(11)C]WAY-100635 (2000) Nucl Med Biol, 27 (5), pp. 509-513; Diaz, M.R., Chappell, A.M., Christian, D.T., Dopamine D3-like receptors modulate anxiety-like behavior and regulate GABAergic transmission in the rat lateral/basolateral amygdala (2011) Neuropsychopharmacology, 36 (5), pp. 1090-1103; Kim, S.W., Fowler, J.S., Skolnick, P., Therapeutic doses of buspirone block D3 receptors in the living primate brain (2014) Int J Neuropsychopharmacol, 17 (8), pp. 1257-1267; Leggio, G.M., Camillieri, G., Platania, C.B., Dopamine D3 receptor is necessary for ethanol consumption: an approach with buspirone (2014) Neuropsychopharmacology, 39 (8), pp. 2017-2028; Farde, L., Ginovart, N., Ito, H., PET-characterization of [carbonyl-11C]WAY-100635 binding to 5-HT1A receptors in the primate brain (1997) Psychopharmacology (Berl), 133 (2), pp. 196-202; Le Foll, B., Boileau, I., Repurposing buspirone for drug addiction treatment (2013) Int J Neuropsychopharmacol, 16 (2), pp. 251-253; Levin, O.S., The use of buspirone in clinical practice (2015) Journal of neurology and psychiatry, 4, pp. 83-87. , Левин О.С. Применение буспирона в клинической практи-ке. Журнал неврологии и психиатрии. 2015;4:83–87. 10.17116/jnevro20151154183-87. [(in Russ)]; Buydens-Branchey, L., Branchey, M., Reel-Brander, C., Efficacy of buspirone in the treatment of opioid withdrawal (2005) J Clin Psychopharmacol, 25 (3), pp. 230-236; Cinciripini, P.M., Lapitsky, L., Seay, S., A placebo-controlled evaluation of the effects of buspirone on smoking cessation: differences between high-and low-anxiety smokers (1995) J Clin Psychopharmacol, 15 (3), pp. 182-191; McRae-Clark, A.L., Baker, N.L., Gray, K.M., Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial (2015) Drug Alcohol Depend, 156, pp. 29-37. , 10.1016/j.drugalcdep.2015.08.013. 48. Garakani A., Murrough J.W., Freire R.C. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Focus (Am Psychiatr Publ). 2021;19(2):222–242; Baldwin, D.S., Anderson, I.M., Nutt, D.J., Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology (2005) J Psychopharmacol, 19 (6), pp. 567-596

PY - 2023

Y1 - 2023

N2 - Buspirone is a representative of an innovative class of anxiolytics (non-benzodiazepine series), used for monotherapy or as part of combined therapy with antidepressants for generalized anxiety disorder, as well as for augmentation of antidepressant therapy. The article is devoted to the buspirone use in the treatment of addictions connected with alcohol, nicotine, opioid. Experimental study results of the buspirone effect on alcohol consumption are presented. The article also describes buspirone mechanisms of action underlying its effects as the additional means for addiction therapy. It is emphasized that azapirone buspirone has little addictive potential, has a favorable safety and tolerability profile, and does not cause withdrawal symptoms. Comorbidity problem of anxiety and alcohol dependence is revealed and complex therapy expediency of such patients is substantiated. Buspirone, a partial agonist of 5-HT1A receptors and an antagonist of dopamine receptors D2, D3 and D4, helps to reduce alcohol consumption, facilitates opioid withdrawal syndrome. It is noted that buspirone has low potential to cause dependence, which may be due to the lack of effect on opiate receptors. It is proved that the effect on dopaminergic receptors of the 3rd subtype can become a new treatment tactics for addiction therapy. © 2023, Meditsina-Inform LLC. All rights reserved.

AB - Buspirone is a representative of an innovative class of anxiolytics (non-benzodiazepine series), used for monotherapy or as part of combined therapy with antidepressants for generalized anxiety disorder, as well as for augmentation of antidepressant therapy. The article is devoted to the buspirone use in the treatment of addictions connected with alcohol, nicotine, opioid. Experimental study results of the buspirone effect on alcohol consumption are presented. The article also describes buspirone mechanisms of action underlying its effects as the additional means for addiction therapy. It is emphasized that azapirone buspirone has little addictive potential, has a favorable safety and tolerability profile, and does not cause withdrawal symptoms. Comorbidity problem of anxiety and alcohol dependence is revealed and complex therapy expediency of such patients is substantiated. Buspirone, a partial agonist of 5-HT1A receptors and an antagonist of dopamine receptors D2, D3 and D4, helps to reduce alcohol consumption, facilitates opioid withdrawal syndrome. It is noted that buspirone has low potential to cause dependence, which may be due to the lack of effect on opiate receptors. It is proved that the effect on dopaminergic receptors of the 3rd subtype can become a new treatment tactics for addiction therapy. © 2023, Meditsina-Inform LLC. All rights reserved.

KW - addictions

KW - alcohol abuse

KW - alcohol dependence

KW - anxiety

KW - buspirone

U2 - 10.32364/2587-6821-2023-7-10-5

DO - 10.32364/2587-6821-2023-7-10-5

M3 - статья

VL - 7

SP - 644

EP - 649

JO - Russian Medical Inquiry

JF - Russian Medical Inquiry

SN - 2587-6821

IS - 10

ER -